Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

RATIONALE: A substantial number of breast cancer patients with an overexpression of the human epidermal growth factor receptor 2 (HER2) have residual disease after neoadjuvant therapy or become resistant to trastuzumab. Photodynamic therapy (PDT) using nanobodies targeted to HER2 is a promising trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Deken, Marion M., Kijanka, Marta M., Hernández, Irati Beltrán, Slooter, Maxime D., de Bruijn, Henriette S., van Diest, Paul J., van Bergen en Henegouwen, Paul M.P., Lowik, Clemens W.G.M., Robinson, Dominic J., Vahrmeijer, Alexander L., Oliveira, Sabrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116241/
https://www.ncbi.nlm.nih.gov/pubmed/32330574
http://dx.doi.org/10.1016/j.jconrel.2020.04.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116241/
https://www.ncbi.nlm.nih.gov/pubmed/32330574
http://dx.doi.org/10.1016/j.jconrel.2020.04.030

Ejemplares similares